prikaz prve stranice dokumenta Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
  Download
PDF 2.84 MB
Scientific paper - Original scientific paper
Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
Modern Pathology, 35 (2022), 12; 1888-1899. https://doi.org/10.1038/s41379-022-01145-0
(ETOP Mesoscape consortium) Rüschoff, Jan Hendrik; Haberecker, Martina; Tsourti, Zoi; Nackaerts, Kristiaan; de Perrot, Marc; Brcic, Luka; Nadal, Ernest; Tsimpoukis, Sotirios; Gray, Steven G.; Ampollini, Luca; Aerts, Joachim G.; Felley-Bosco, Emanuela; Kirschner, Michaela B.; Monkhorst, Kim; Weynand, Birgit; Bavaghar-Zaeimi, Fatemeh; Samaržija, Miroslav; Llatjos, Roger; Finn, Stephen P.; Silini, Enrico; von der Thüsen, Jan; Marti, Nesa; Vervita, Karerina; Kammler, Roswitha; Peters, Solange; Stahel, Rolf A.; Baas, Paul; Opitz, Isabelle; Stahel, Rolf; Hiltbrunner, Anita; Kammler, Rosita; Marti, Nesa; Vagenknecht, Patrick; Ruepp, Barbara; Dafni, Urania; Tsourti, Zoi; Zygoura, Panagiota; Vervita, Katerina; Dimopoulou, Georgia; Andriakopoulou, Charitini; Stavrou, Androniki; Rüschoff, Jan H.; Haberecker, Martina; Dettwiler, Susanne; Prutek, Fabiola; Mittmann, Christiane; Opitz, Isabelle More authors...

Cite this document

Rüschoff, J. H., Haberecker, M., Tsourti, Z., Nackaerts, K., de Perrot, M., Brcic, L. ... Opitz, I. (2022). Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project. Modern Pathology, 35. (12), 1888-1899. doi: 10.1038/s41379-022-01145-0

Rüschoff, Jan Hendrik, et al. "Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project." Modern Pathology, vol. 35, no. 12, 2022, pp. 1888-1899. https://doi.org/10.1038/s41379-022-01145-0

Rüschoff, Jan Hendrik, Martina Haberecker, Zoi Tsourti, Kristiaan Nackaerts, Marc de Perrot, Luka Brcic, Ernest Nadal, et al. "Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project." Modern Pathology 35, no. 12 (2022): 1888-1899. https://doi.org/10.1038/s41379-022-01145-0

Rüschoff, J. H., et al. (2022) 'Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project', Modern Pathology, 35(12), pp. 1888-1899. doi: 10.1038/s41379-022-01145-0

Rüschoff JH, Haberecker M, Tsourti Z, Nackaerts K, de Perrot M, Brcic L, and sur.. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project. Modern Pathology [Internet]. 2022 December [cited 2024 September 28];35(12):1888-1899. doi: 10.1038/s41379-022-01145-0

J. H. Rüschoff, et al., "Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project", Modern Pathology, vol. 35, no. 12, pp. 1888-1899, December 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:000556. [Accessed: 28 September 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project
AuthorJan Hendrik Rüschoff
AuthorMartina Haberecker
AuthorZoi Tsourti
AuthorKristiaan Nackaerts
AuthorMarc de Perrot
AuthorLuka Brcic
AuthorErnest Nadal
AuthorSotirios Tsimpoukis
AuthorSteven G. Gray
AuthorLuca Ampollini
AuthorJoachim G. Aerts
AuthorEmanuela Felley-Bosco
AuthorMichaela B. Kirschner
AuthorKim Monkhorst
AuthorBirgit Weynand
AuthorFatemeh Bavaghar-Zaeimi
AuthorMiroslav Samaržija
AuthorRoger Llatjos
AuthorStephen P. Finn
AuthorEnrico Silini
AuthorJan von der Thüsen
AuthorNesa Marti
AuthorKarerina Vervita
AuthorRoswitha Kammler
AuthorSolange Peters
AuthorRolf A. Stahel
AuthorPaul Baas
AuthorIsabelle Opitz
AuthorRolf Stahel
AuthorAnita Hiltbrunner
AuthorRosita Kammler
AuthorNesa Marti
AuthorPatrick Vagenknecht
AuthorBarbara Ruepp
AuthorUrania Dafni
AuthorZoi Tsourti
AuthorPanagiota Zygoura
AuthorKaterina Vervita
AuthorGeorgia Dimopoulou
AuthorCharitini Andriakopoulou
AuthorAndroniki Stavrou
AuthorJan H. Rüschoff
AuthorMartina Haberecker
AuthorSusanne Dettwiler
AuthorFabiola Prutek
AuthorChristiane Mittmann
AuthorIsabelle Opitz
CollaborationETOP Mesoscape consortium
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis. Although histology and pathologic stage are important prognostic factors, better prognostic biomarkers are needed. The ribosomal protein S6 is a downstream target of the phosphatidylinositol 3-kinase (PI3K) pathway involved in protein synthesis and cell proliferation. In previous studies, low phosphorylated S6 (pS6) immunoreactivity was significantly correlated with longer progression-free survival (PFS) and overall survival (OS) in PM patients. We aimed to correlate pS6 expression to clinical data in a large multi-centre PM cohort as part of the European Thoracic Oncology Platform (ETOP) Mesoscape project. Tissue Micro Arrays (TMAs) of PM were constructed and expression of pS6 was evaluated by a semi-quantitatively aggregate H-score. Expression results were correlated to patient characteristics as well as OS/PFS. pS6 IHC results of 364 patients from 9 centres, diagnosed between 1999 and 2017 were available. The primary histology of included tumours was epithelioid (70.3%), followed by biphasic (24.2%) and sarcomatoid (5.5%). TMAs included both treatment-naïve and tumour tissue taken after induction chemotherapy. High pS6 expression (181 patients with H-score>1.41) was significantly associated with less complete resection. In the overall cohort, OS/PFS were not significantly different between pS6-low and pS6-high patients. In a subgroup analysis non-epithelioid (biphasic and sarcomatoid) patients with high pS6 expression showed a significantly shorter OS (p < 0.001, 10.7 versus 16.9 months) and PFS (p < 0.001, 6.2 versus 10.8 months). In subgroup analysis, in non-epithelioid PM patients high pS6 expression was associated with significantly shorter OS and PFS. These exploratory findings suggest a clinically relevant PI3K pathway activation in non-epithelioid PM which might lay the foundation for future targeted treatment strategies.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleModern Pathology
Numberingvol. 35, no. 12, pp. 1888-1899
p-ISSN0893-3952
DOIhttps://doi.org/10.1038/s41379-022-01145-0
URN:NBNurn:nbn:hr:105:000556
Publication2022-12
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0893395222055016
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2023-02-14 08:10:35